Creating a new generation of small molecule protease inhibitors

Overview

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.

Medic-patient meeting

KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need. KalVista has built an expanding clinical and advanced preclinical product pipeline targeting multiple routes of administration to treat these diseases.

Research and Development

KalVista’s initial focus is on advancing a portfolio of orally delivered plasma kallikrein inhibitors for the treatment of HAE. The most advanced program, KVD818, is in Phase I clinical studies and additional molecules are expected to reach the clinic in 2017. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 clinical studies.

KalVista has an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.

KalVista has offices in Cambridge, MA, USA and Salisbury, UK.